By combining trusted community engagement, personalized education, and behavioral insights to support individuals throughout every stage of clinical research.

Understanding each stage helps organizations improve communication, reduce drop-off, and create a better experience for participants.

It begins when someone first becomes aware of a clinical research opportunity, often before they consider participating.

They help sponsors improve recruitment efficiency, strengthen representation, and reduce enrollment risk by informing decisions before challenges arise.

Acclinate combines community engagement, behavioral data, and its patented e-DICT™ technology to identify patterns that support more effective outreach.

Traditional analytics explain what has happened. Predictive insights estimate what is likely to happen next using behavioral and engagement data.

Behavioral data provides measurable insights into how individuals engage at each stage, helping organizations make evidence-based improvements.

No. It can support health education, community engagement, and healthcare outreach initiatives.

It helps organizations identify where individuals disengage so outreach strategies can be improved.

Yes. Early community involvement often leads to stronger engagement and more representative enrollment.

Yes. Collaborative partnerships help build long-term trust and increase participation.

Community members help shape research priorities and engagement strategies rather than participating only as study subjects.

Through continuous education, community partnerships, transparent communication, and ongoing engagement.

It helps organizations build trust and awareness before recruitment begins, improving participation and reducing enrollment delays.

No. Eligibility determines whether someone qualifies for a study. Clinical readiness reflects whether they are informed and prepared to consider participation.

By engaging communities early, monitoring enrollment data, and adapting outreach strategies based on measurable insights.

Yes. It includes investigators, advisory boards, and leadership.

‍

It improves the reliability and applicability of research findings.

‍

By measuring gaps, engaging communities, and adjusting strategies based on data and lived experience.

‍

It improves access, participation, and the relevance of study results.

‍

No. Equality provides the same resources to everyone. Equity adjusts support based on need.

Yes. Early efforts to diversify enrollment helps prevent late-stage recruitment shortfalls that can lead to riskier market rollouts.

It is measured by comparing participant demographics to disease prevalence and target populations.

‍

Common barriers to participation include mistrust, limited access, logistical barriers, and ineffective outreach.

Sponsors are expected to submit diversity action plans outlining strategies for underrepresented groups.

When collected and analyzed responsibly, it can support engagement strategies while respecting data protection standards.

It reveals where potential participants disengage and where trust gaps may exist.

Demographic data describes identity traits. Behavioral data reflects actions and engagement patterns

Yes. It strengthens generalizability and increases confidence in treatment safety and efficacy.

Sponsors, sites, and communities alike.

Yes, while maintaining local relevance.

It informs messaging, site strategy, and participant experience.

No. The model supports engagement across the full research lifecycle, harnessing a thorough community network to encourage

Combining authentic community engagement with advanced analytics, our model embeds inclusion into clinical research well before participant enrollment. This not only allows for more effective treatment rollouts downstream, but also encourages action toward better health.

Yes, with increasing value over time. As your organization partners with Acclinate, your data will improve while strategies enhance representation efforts.

Yes. Acclinate accelerates research by reducing late-stage corrections, expanding participant pools, and helping sponsors reach equity goals.

No. It informs and strengthens it, amplifying authentic engagement into tangible data for better research programs.

Identifying where engagement and access barriers may arise early, our intelligent platform equips decision-makers with the best quality insights they need to concentrate their enrollment efforts.

It uses community engagement data patterns to anticipate enrollment performance and gaps.

Yes, while maintaining cultural and contextual relevance.

Sponsors, sites, and communities alike.

Yes, while maintaining local relevance.

It informs messaging, site strategy, and participant experience.

No. The model supports engagement across the full research lifecycle, harnessing a thorough community network to encourage

Combining authentic community engagement with advanced analytics, our model embeds inclusion into clinical research well before participant enrollment. This not only allows for more effective treatment rollouts downstream, but also encourages action toward better health.

Sponsors, CROs, and research teams benefit by gaining clearer insight into site readiness and engagement performance before and during studies. {{cta('2daa6753-37c3-421c-a858-ea4e51d5f618')}}

SEI is designed to support ongoing site readiness assessment, allowing progress and improvement to be tracked over time.

Community trust metrics help identify whether engagement efforts are building credibility and sustained participation, which directly affects enrollment and retention.

SEI focuses on engagement quality and trust rather than volume-based indicators such as outreach counts or enrollment speed alone.

The Site Engagement Index (SEI) is a framework developed to assess how ready research sites are to engage communities effectively and equitably.

Yes. Acclinate accelerates research by reducing late-stage corrections, expanding participant pools, and helping sponsors reach equity goals.

Yes, with increasing value over time. As your organization partners with Acclinate, your data will improve while strategies enhance representation efforts.

No. It informs and strengthens it, amplifying authentic engagement into tangible data for better research programs.

Identifying where engagement and access barriers may arise early, our intelligent platform equips decision-makers with the best quality insights they need to concentrate their enrollment efforts.

It uses community engagement data patterns to anticipate enrollment performance and gaps.

No. It supports engagement across recruitment, retention, and long-term community relationships.

No. It supports teams by informing strategy and improving responsiveness. No technology can replace authentic, human connection.

It incorporates engagement behavior and community insight rather than relying only on static demographics.

Yes, NOWINCLUDED supports all United States-based users while maintaining local relevance through community events and opportunities to connect.

e-DICT™ is Acclinate’s proprietary engine for engagement-driven, intelligent community targeting.

By elevating community insight earlier and more consistently. Importantly, NOWINCLUDED encourages discourse and storytelling about first-hand health experiences, giving people the outlet they need to better understand and own their care journeys.

No. It supports education and engagement beyond specific studies, supporting health equity initiatives across the healthcare continuum.

Anyone can join, not necessarily just those who are interested in health topics/research. People can use the platform to make their voice heard in healthcare or simply seek community.

A community engagement platform that offers a safe space for people in underrepresented communities to be heard and supported throughout their health journeys.

From the beginning stages of clinical trials, well before recruitment starts.

Yes. Federal guidance and peer-reviewed regulatory commentary emphasize aligning enrollment with intended use populations to support reliable benefit–risk assessments.

Real-world data can help contextualize outcomes, but it does not replace representative enrollment in pivotal studies. Strong clinical trial management integrates both.

Under FDA clinical research regulations, regulators evaluate whether pivotal trial populations reflect intended use populations. Weak generalizability may lead to labeling limitations or postmarketing requirements.

Sponsors can align enrollment targets with disease epidemiology, broaden eligibility criteria when appropriate, collect complete demographic data, and engage communities early in recruitment planning.

When inclusion strategies are embedded early, they often stabilize recruitment rather than delay it. Late adjustments tend to introduce greater operational disruption.

Diversity metrics indicate how well trial populations reflect real-world disease burden. Misalignment can lead to additional analyses, labeling limitations, or postmarketing requirements.

When only one trial supports approval, there are fewer opportunities to validate findings across diverse populations. Limited representation increases uncertainty in safety and effectiveness for underrepresented groups.

Recent FDA guidance and related commentary emphasize that credible evidence requires representative enrollment across clinically relevant subgroups.

Postmarketing requirements may obligate sponsors to conduct additional safety or effectiveness studies in underrepresented populations if the original trial lacked sufficient representation.

Clinical trial generalizability refers to how well study findings apply to broader patient populations beyond the enrolled sample. It determines whether safety and efficacy conclusions extend to real-world use.

Diversity planning should begin early. Retrofitting inclusion strategies mid-trial often increases cost and complexity. Early planning improves enrollment stability and regulatory defensibility.

Equitable research improves data generalizability, strengthens labeling, increases clinician confidence, and reduces the likelihood of postapproval surprises that can affect payer coverage or prescribing patterns.

If enrollment does not meet diversity expectations outlined in diversity action plans, the FDA may request additional analyses or data. These requests can slow review cycles or create conditional approvals tied to future studies.

Regulators increasingly evaluate whether trial populations reflect real-world disease burden. Insufficient representation can trigger approval delays, labeling limitations, or postmarketing study requirements, which introduce financial and operational risk.